| HOME >> BIOLOGY >> TECHNOLOGY |
FRAZER, Pa., Oct. 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its Analyst Day in New York City, to be held on November 5, 2008, will be webcast live on the investor relations section of its website at http://www.cephalon.com.
Cephalon's senior management will review the company's business strategy, marketing plan and research and development initiatives. The presentations will be delivered on Wednesday, November 5, 2008 beginning at approximately 12:30 p.m. EST and ending at 3:15 p.m. EST. The webcast will be archived for one week following the broadcast. To access the webcast, log on to the company's website at http://www.cephalon.com and click on "Investors," then "Webcast." Click on the link and follow the prompts for registration and access.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.
The company's proprietary products in the United States include:
TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R)
(cyclobenzaprine hydrochloride extended-release capsules), PROVIGIL(R)
(modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [CII],
TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for
extended-release injectable suspension), GABITRIL(R
'/>"/>
| SOURCE Cephalon, Inc. Copyright©2008 PR Newswire. All rights reserved |